373 related articles for article (PubMed ID: 16736512)
1. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.
Rini BI; Weinberg V; Fong L; Conry S; Hershberg RM; Small EJ
Cancer; 2006 Jul; 107(1):67-74. PubMed ID: 16736512
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.
Burch PA; Croghan GA; Gastineau DA; Jones LA; Kaur JS; Kylstra JW; Richardson RL; Valone FH; Vuk-Pavlović S
Prostate; 2004 Aug; 60(3):197-204. PubMed ID: 15176049
[TBL] [Abstract][Full Text] [Related]
3. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.
Beinart G; Rini BI; Weinberg V; Small EJ
Clin Prostate Cancer; 2005 Jun; 4(1):55-60. PubMed ID: 15992463
[TBL] [Abstract][Full Text] [Related]
4. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
5. Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial.
Antonarakis ES; Kibel AS; Yu EY; Karsh LI; Elfiky A; Shore ND; Vogelzang NJ; Corman JM; Millard FE; Maher JC; Chang NN; DeVries T; Sheikh NA; Drake CG;
Clin Cancer Res; 2017 May; 23(10):2451-2459. PubMed ID: 27836866
[No Abstract] [Full Text] [Related]
6. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge).
Harzstark AL; Small EJ
Expert Opin Biol Ther; 2007 Aug; 7(8):1275-80. PubMed ID: 17696825
[TBL] [Abstract][Full Text] [Related]
7. Sipuleucel-T (APC8015) for prostate cancer.
So-Rosillo R; Small EJ
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1163-7. PubMed ID: 17020451
[TBL] [Abstract][Full Text] [Related]
8. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.
Burch PA; Breen JK; Buckner JC; Gastineau DA; Kaur JA; Laus RL; Padley DJ; Peshwa MV; Pitot HC; Richardson RL; Smits BJ; Sopapan P; Strang G; Valone FH; Vuk-Pavlović S
Clin Cancer Res; 2000 Jun; 6(6):2175-82. PubMed ID: 10873066
[TBL] [Abstract][Full Text] [Related]
9. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer.
Sims RB
Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856
[TBL] [Abstract][Full Text] [Related]
10. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.
Thara E; Dorff TB; Pinski JK; Quinn DI
Maturitas; 2011 Aug; 69(4):296-303. PubMed ID: 21621934
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
Small EJ; Fratesi P; Reese DM; Strang G; Laus R; Peshwa MV; Valone FH
J Clin Oncol; 2000 Dec; 18(23):3894-903. PubMed ID: 11099318
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.
Beer TM; Bernstein GT; Corman JM; Glode LM; Hall SJ; Poll WL; Schellhammer PF; Jones LA; Xu Y; Kylstra JW; Frohlich MW
Clin Cancer Res; 2011 Jul; 17(13):4558-67. PubMed ID: 21558406
[TBL] [Abstract][Full Text] [Related]
13. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer.
Rini BI; Weinberg V; Bok R; Small EJ
J Clin Oncol; 2003 Jan; 21(1):99-105. PubMed ID: 12506177
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells.
Lin AM; Hershberg RM; Small EJ
Urol Oncol; 2006; 24(5):434-41. PubMed ID: 16962496
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.
McNeel DG; Dunphy EJ; Davies JG; Frye TP; Johnson LE; Staab MJ; Horvath DL; Straus J; Alberti D; Marnocha R; Liu G; Eickhoff JC; Wilding G
J Clin Oncol; 2009 Sep; 27(25):4047-54. PubMed ID: 19636017
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer.
Schellhammer PF; Hershberg RM
World J Urol; 2005 Feb; 23(1):47-9. PubMed ID: 15647927
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer.
Fucikova J; Podrazil M; Jarolim L; Bilkova P; Hensler M; Becht E; Gasova Z; Klouckova J; Kayserova J; Horvath R; Fialova A; Vavrova K; Sochorova K; Rozkova D; Spisek R; Bartunkova J
Cancer Immunol Immunother; 2018 Jan; 67(1):89-100. PubMed ID: 28948333
[TBL] [Abstract][Full Text] [Related]
19. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Gulley JL; Arlen PM; Bastian A; Morin S; Marte J; Beetham P; Tsang KY; Yokokawa J; Hodge JW; Ménard C; Camphausen K; Coleman CN; Sullivan F; Steinberg SM; Schlom J; Dahut W
Clin Cancer Res; 2005 May; 11(9):3353-62. PubMed ID: 15867235
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer.
Twardowski P; Wong JYC; Pal SK; Maughan BL; Frankel PH; Franklin K; Junqueira M; Prajapati MR; Nachaegari G; Harwood D; Agarwal N
Cancer Treat Res Commun; 2019; 19():100116. PubMed ID: 30682445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
